Lupin to produce additional strengths of cholesterol drug

Mumbai-based drug company Lupin announced the approval of additional strengths of its cholesterol lowering drug by the USFDA. The company has received USFDA’s approval for marketing additional strengths of its cholesterol lowering drug capsules, names Antara in the US market.
According to the company’s announcement, the final approval for supplemental New Drug Application (sNDA) for the given Antara capsules has been received. These capsules contain fenofibrate in the strengths of 30 mg and 90 mg, which has been approved by the USFDA. The marketing of this product would soon commence and would be managed by the company’s US subsidiary, Lupin Pharmaceuticals Inc (LPI).

The company LPI presently markets 43 mg and 130 mg of Antara capsules manufactured by Ethypharm. Now with the approval of additional strengths, the company would manufacture 30 mg and 90 mg of Antara capsules in India and would turn out to be more profitable.